Advances in the detection of Alzheimer's disease - Use of cerebrospinal fluid biomarkers

Clinica Chimica Acta

Volumn 332, Issue 1-2, 2003, Pages 1-10

  Sjögren, Magnus ^a   Andreasen, Niels ^b   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Biochemical markers; Cerebrospinal fluid; Diagnosis; Mild cognitive impairment; Tau; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; EPITOPE; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD ANALYSIS; BRAIN SCINTISCANNING; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVIEW; SYMPTOM;

EID: 0037986691     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00121-9     Document Type: Review

References (58)

1. Wimo A., Jönsson L. Demenssjukdomarnas samhällskostnader. 2001;Socialstyrelsen, Stockholm.
2. Blennow K., Skoog I. Genetic testing for Alzheimer's disease: how close is reality? Curr. Opin. Psychiatry. 12:1999;487-493.
3. Tamaoka A., Sawamura N., Odaka A.et al. Amyloid beta protein 1-42/43 (A beta 1-42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study. Brain Res. 679:1995;151-156.
4. Goedert M., Wischik C.M., Crowther R.A., Walker J.E., Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U. S. A. 85:1988;4051-4055.
5. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report on the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 34:1984;939-944.
6. Tierney M.C., Fisher R.H., Lewis A.J.et al. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases. Neurology. 38:1988;359-364.
7. Galasko D., Hansen L.A., Katzman R.et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch. Neurol. 51:1994;888-895.
8. Geddes J.W., Tekirian T.L., Soultanian N.S., Ashford J.W., Davis D.G., Markesbery W.R. Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurobiol. Aging. 18:1997;S99-S105.
9. Consensus report of the Working group on "Molecular and biochemical markers of Alzheimer's disease" Neurobiol. Aging. 19:1998;109-116.
10. Fishman R.A. Cerebrospinal fluid in diseases of the nervous system. 1980;WB Saunders, Philadelphia.
11. Thompson E.J. The CSF proteins: a biomedical approach. 1988;117-120 Elsevier, Amsterdam.
12. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 16:1993;460-465.
13. Vandermeeren M., Mercken M., Vanmechelen E.et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61:1993;1828-1834.
14. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26:1995;231-245.
15. Vigo-Pelfrey C., Seubert P., Barbour R.et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology. 45:1995;788-793.
16. Green A.J., Harvey R.J., Thompson E.J., Rossor M.N. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci. Lett. 259:1999;133-135.
17. Molina L., Touchon J., Herpe M.et al. Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. Neuroreport. 10:1999;3491-3495.
18. Andreasen N., Minthon L., Davidsson P.et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58:2001;373-379.
19. Morikawa Y., Arai H., Matsushita S.et al. Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. Alcohol Clin. Exp. Res. 23:1999;575-577.
20. Urakami K., Mori M., Wada K.et al. A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy. Neurosci. Lett. 259:1999;127-129.
21. Hesse C., Rosengren L., Vanmechelen E.et al. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J. Alzheimer's Dis. 2:2000;199-206.
22. Otto M., Wiltfang J., Tumani H.et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225:1997;210-212.
23. Tapiola T., Overmyer M., Lehtovirta M.et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport. 8:1997;3961-3963.
24. Sjogren M., Davidsson P., Gottfries J.et al. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement. Geriatr. Cogn. Disord. 12:2001;257-264.
25. Haass C., Hung A.Y., Schlossmacher M.G., Oltersdorf T., Teplow D.B., Selkoe D.J. Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. Ann. N. Y. Acad. Sci. 695:1993;109-116.
26. Motter R., Vigo Pelfrey C., Kholodenko D.et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38:1995;643-648.
27. Tamaoka A., Sawamura N., Fukushima T.et al. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J. Neurol. Sci. 148:1997;41-45.
28. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57:2000;100-105.
29. Vanderstichele H., Blennow K., D'Heuvaert N.et al. Development of a specific diagnostic test for measurement of b-amyloid(1-42) in CSF. Fisher A., Hanin I., Yoshida M. Progress in Alzheimer's and Parkinson's diseases. 1998;773-778 Plenum, New York.
30. Kanemaru K., Kameda N., Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology. 54:2000;1875-1876.
31. Hulstaert F., Blennow K., Ivanoiu A.et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology. 52:1999;1555-1562.
32. Sjogren M., Minthon L., Davidsson P.et al. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural Transm. 107:2000;563-579.
33. Otto M., Esselman H., Schultz-Schaeffer W.et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jacob disease. Neurology. 54:2000;1099-1102.
34. Kapaki E., Kilidireas K., Paraskevas G.P., Michalopoulou M., Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease? J. Neurol. Neurosurg. Psychiatry. 71:2001;401-403.
35. Sjogren M., Davidsson P., Wallin A.et al. Decreased CSF-[beta]-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of [beta]-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord. 13:2002;112-118.
36. Ichihara N., Wu J., Chui D.H., Yamazaki K., Wakabayashi T., Kikuchi T. Axonal degeneration promotes abnormal accumulation of amyloid beta-protein in ascending gracile tract of gracile axonal dystrophy (GAD) mouse. Brain Res. 695:1995;173-178.
37. Sjogren M., Gisslen M., Vanmechelen E., Blennow K. Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci. Lett. 314:2001;33-36.
38. Ferreira A., Busciglio J., Caceres A. Microtubule formation and neurite growth in cerebellar macroneurons which develop in vitro: evidence for the involvement of the microtubule-associated proteins, MAP-1a, HMW-MAP2 and Tau. Brain Res. Dev. Brain Res. 49:1989;215-228.
39. Iqbal K., Grundke-Iqbal I. Mechanism of Alzheimer neurofibrillary degeneration and the formation of tangles. Mol. Psychiatry. 2:1997;178-180.
40. Vanmechelen E., Vanderstichele H., Davidsson P.et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285:2000;49-52.
41. Ishiguro K., Ohno H., Arai H.et al. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci. Lett. 270:1999;91-94.
42. Kohnken R., Buerger K., Zinkowski R.et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 287:2000;187-190.
43. Hu Y.Y., He S.S., Wang X.et al. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am. J. Pathol. 160:2002;1269-1278.
44. Sjogren M., Davidsson P., Tullberg M.et al. Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 70:2001;624-630.
45. Parnetti L., Lanari A., Amici S., Gallai V., Vanmechelen E., Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol. Sci. 22:2001;77-78.
46. Hesse C., Rosengren L., Andreasen N.et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 297:2001;187-190.
47. Galasko D., Chang L., Motter R.et al. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol. 55:1998;937-945.
48. Kanai M., Matsubara E., Isoe K.et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 44:1998;17-26.
49. Andreasen N., Minthon L., Davidsson P.et al. Evaluation of CSF-tau and CSF-AB42 as diagnostic markers for Alzheimer's disease in clinical practice. Arch. Neurol. 58:2001;373-379.
50. Andreasen N., Minthon L., Vanmechelen E.et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. 273:1999;5-8.
51. Kurz A., Riemenschneider M., Buch K.et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 12:1998;372-377.
52. Riemenschneider M., Buch K., Schmolke M., Kurz A., Guder W.G. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci. Lett. 212:1996;209-211.
53. Riemenschneider M., Schmolke M., Lautenschlager N.et al. Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci. Lett. 284:2000;85-88.
54. Arai H., Ishiguro K., Ohno H.et al. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp. Neurol. 166:2000;201-203.
55. Buerger K., Teipel S.J., Zinkowski R.et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 59:2002;627-629.
56. Davies L., Wolska B., Hilbich C.et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology. 38:1988;1688-1693.
57. Roberts G.W., Gentleman S.M., Lynch A., Murray L., Landon M., Graham D.I. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 57:1994;419-425.
58. McKenzie J.E., Gentleman S.M., Roberts G.W., Graham D.I., Royston M.C. Increased numbers of beta APP-immunoreactive neurones in the entorhinal cortex after head injury. Neuroreport. 6:1994;161-164.